53 related articles for article (PubMed ID: 17518268)
1. ECTO-NOX target for the anticancer isoflavene phenoxodiol.
Morré DJ; Chueh PJ; Yagiz K; Balicki A; Kim C; Morré DM
Oncol Res; 2007; 16(7):299-312. PubMed ID: 17518268
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients.
Cho N; Chueh PJ; Kim C; Caldwell S; Morré DM; Morré DJ
Cancer Immunol Immunother; 2002 May; 51(3):121-9. PubMed ID: 11941450
[TBL] [Abstract][Full Text] [Related]
3. Spectroscopic Analyses of Oscillations in ECTO-NOX-Catalyzed Oxidation of NADH.
Morré DJ; Morré DM
Nonlinearity Biol Toxicol Med; 2003 Jul; 1(3):345-62. PubMed ID: 19330139
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Dextran-Phenoxodiol and Evaluation of Its Physical Stability and Biological Activity.
Yee EMH; Cirillo G; Brandl MB; Black DS; Vittorio O; Kumar N
Front Bioeng Biotechnol; 2019; 7():183. PubMed ID: 31440502
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of ME-344, a novel cytotoxic isoflavone.
Zhang L; Zhang J; Ye Z; Townsend DM; Tew KD
Adv Cancer Res; 2019; 142():187-207. PubMed ID: 30885362
[TBL] [Abstract][Full Text] [Related]
6. ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent nasopharyngeal carcinoma.
Kam NW; Laczka O; Li X; Wilkinson J; Hung D; Lai SPH; Wu KC; Tsao SW; Dai W; Che CM; Lee VH; Kwong DL
J Adv Res; 2024 Feb; 56():69-86. PubMed ID: 37061217
[TBL] [Abstract][Full Text] [Related]
7. The role of isoflavones in augmenting the effects of radiotherapy.
Ivashkevich A
Front Oncol; 2022; 12():800562. PubMed ID: 36936272
[TBL] [Abstract][Full Text] [Related]
8. NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study.
Kiknavelidze K; Shavdia M; Chikhladze N; Abshilava L; Messina M; Mautner G; Kelly G
Curr Ther Res Clin Exp; 2021; 94():100631. PubMed ID: 34306271
[TBL] [Abstract][Full Text] [Related]
9. Triggering of eryptosis, the suicidal erythrocyte death, by phenoxodiol.
Fink M; Bhuyan AAM; Nürnberg B; Faggio C; Lang F
Naunyn Schmiedebergs Arch Pharmacol; 2019 Oct; 392(10):1311-1318. PubMed ID: 31280326
[TBL] [Abstract][Full Text] [Related]
10. Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-
Lin CY; Islam A; Su CJ; Tikhomirov AS; Shchekotikhin AE; Chuang SM; Chueh PJ; Chen YL
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909652
[TBL] [Abstract][Full Text] [Related]
11. Selected Office Based Anticancer Treatment Strategies.
Stoff JA
J Oncol; 2019; 2019():7462513. PubMed ID: 30766601
[TBL] [Abstract][Full Text] [Related]
12. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
Chen HY; Islam A; Yuan TM; Chen SW; Liu PF; Chueh PJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):161. PubMed ID: 30029680
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.
Stevenson AJ; Ager EI; Proctor MA; Škalamera D; Heaton A; Brown D; Gabrielli BG
Sci Rep; 2018 Mar; 8(1):5144. PubMed ID: 29572477
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells.
Chen HY; Cheng HL; Lee YH; Yuan TM; Chen SW; Lin YY; Chueh PJ
Oncotarget; 2017 Feb; 8(9):15338-15348. PubMed ID: 28122359
[TBL] [Abstract][Full Text] [Related]
15. Update on a tumor-associated NADH oxidase in gastric cancer cell growth.
Cheng HL; Lee YH; Yuan TM; Chen SW; Chueh PJ
World J Gastroenterol; 2016 Mar; 22(10):2900-5. PubMed ID: 26973386
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I).
Lim SC; Carey KT; McKenzie M
Am J Cancer Res; 2015; 5(2):689-701. PubMed ID: 25973307
[TBL] [Abstract][Full Text] [Related]
17. ENOX2 target for the anticancer isoflavone ME-143.
Morré DJ; Korty T; Meadows C; Ades LM; Morré DM
Oncol Res; 2014; 22(1):1-12. PubMed ID: 25700353
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
Pant S; Burris HA; Moore K; Bendell JC; Kurkjian C; Jones SF; Moreno O; Kuhn JG; McMeekin S; Infante JR
Invest New Drugs; 2014 Feb; 32(1):87-93. PubMed ID: 23525756
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin.
Schwartz L; Guais A; Israël M; Junod B; Steyaert JM; Crespi E; Baronzio G; Abolhassani M
Invest New Drugs; 2013 Apr; 31(2):256-64. PubMed ID: 22797854
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
